ArticleIranian journal of pharmaceutical research : IJPR
Cost-Utility Analysis of Mirabegron Compared to Solifenacin in the Treatment of Overactive Bladder (OAB) in Iran.
Zahra Karimi Majd et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.